Desicorp, Inc.
Louisville, KY
- UEI
- KNA4L6N847S3
- CAGE
- 8AUB9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- Louisville, KY RSBWGXWSJDJ6
- Louisville, KY USX9TM9TGPE7
- Louisville, KY YYS3DMR93KZ7
-
- SAM.gov registration date
- Physical address
- 201 E Jefferson St #309, Louisville, KY 40202, USA
- Website
- desicorpinc.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $74,698 |
Contract awards
Grant awards
About the company
Desicorp, Inc. Division is a corporate entity registered to receive federal contracts and grants from the U.S. government. It operates as a for-profit manufacturer of goods.
Through federal contract awards, Desicorp has provided research and development services related to medical technologies. In 2022, the company received a Small Business Innovation Research (SBIR) Phase I contract from the Department of the Air Force Materiel Command Research Laboratory to develop a rehydration system for lyophilized blood products. This $74,698 contract was set aside for small businesses. Additionally, in 2020, Desicorp was awarded a $249,957.36 firm-fixed-price SBIR Phase I contract from the Defense Health Agency to conduct research on developing a thermally stable whole blood product for transfusion. Both contracts involved early-stage research efforts focused on improving blood product storage and transportation.
Desicorp has also received federal grant funding for research and development projects. In February 2023, the National Institutes of Health (NIH) National Center for Advancing Translational Sciences awarded the company a $563,746 project grant to develop a high-flow acoustofluidic loading platform for stabilizing research cells in an anhydrous state. The grant supports research aimed at creating a method for lyophilizing (freeze-drying) eukaryotic cells, allowing for their long-term storage at ambient temperatures without the need for cryogenic freezers or liquid nitrogen. This project aims to address challenges in preserving cell stocks for cancer research and drug discovery applications.
Quick answers
Is Desicorp, Inc. registered in SAM.gov?
Yes. Desicorp, Inc.'s SAM.gov registration is active through September 22, 2027.
How much has Desicorp, Inc. received in federal contracts?
Federal contracts obligated $74,698 to Desicorp, Inc. in fiscal years 2023 through 2027.
What is Desicorp, Inc.'s most recent federal award?
Desicorp, Inc.'s most recent federal grant award is Developing a high-flow acoustofluidic loading platform for research cell stabilization in the anhydrous state (R43TR004327), from National Center for Advancing Translational Sciences (NIH), on February 1, 2023.
On GovTribe
See Desicorp, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors